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Abstract: Eosinophils are important proinflammatory cells that make a major contribution 
to the inflammation seen in allergic diseases including asthma. Interleukin-5 is central to 
 eosinophil maturation, release from the bone marrow, and subsequent accumulation, activation, 
and persistence in the tissues. Reslizumab (Cinquil™) is a humanized monoclonal antibody 
with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly 
controlled eosinophilic asthma. This review will consider the current status of the clinical 
development of reslizumab for asthma and in other inflammatory diseases with a marked 
eosinophilic component.
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Introduction
Eosinophil involvement in inflammatory conditions affecting the skin, gastrointesti-
nal tract, and upper and lower airways is well documented.1 Eosinophilic asthma is a 
phenotype of the condition characterized by increased blood or sputum eosinophils 
whose numbers correlate with disease severity.2 Infiltrating tissue eosinophils release 
their potent proinflammatory arsenal including granule-derived basic proteins, lipid 
mediators, cytokines, and chemokines. These contribute to airway inflammation and 
lung tissue remodeling that includes airway thickening, fibrosis, and angiogenesis.3 
More recent evidence suggests that in addition to their role as degranulating effector 
cells, eosinophils have the capacity to act as antigen presenting cells resulting in T cell 
proliferation and activation.4 The crucial role of interleukin (IL)-5 in the development 
and release of eosinophils from the bone marrow, their enhanced  adhesion to endothelial 
cells lining the post-capillary venules, their activation, secretion, and prolonged survival 
through apoptosis inhibition in the tissues has been known for many years.5,6 IL-5 
was therefore identified as a promising target to prevent or blunt eosinophil-mediated 
inflammation in patients with asthma and other eosinophil-related conditions, leading 
to the development of humanized anti-IL-5 monoclonal antibodies (mAb) such as 
mepolizumab and reslizumab or benralizumab, a mAb against human IL-5Rα.7–10
Several early clinical trials in patients with mild to severe asthma that examined the 
effects of the anti-IL-5 mAb mepolizumab reported significant depletion of blood and 
sputum eosinophils. However, clinical outcomes were disappointing as there were no 
significant effects on airway hyperreactivity or the late asthmatic reaction to inhaled 
allergen challenge.11–14 It is important to note that these studies all used subjects recruited 
on the basis of clinical and physiological characteristics not associated with the presence 
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of eosinophilic airway inflammation.15 Furthermore, IL-5 is 
not the sole factor responsible for eosinophil accumulation, 
persistence, secretion, and other activities in tissues. Other fac-
tors likely to make important contributions to these processes 
include granulocyte macrophage colony-stimulating factor, 
IL-3, IL-9, and IL-13.16
It is now appreciated that the pathophysiological asthma 
phenotypes need to be determined prior to the selection of 
patients for biologic therapy in asthma. Such an approach 
is supported by two more recent studies in highly selected 
asthma patient populations with a demonstrable sputum 
eosinophilia. These studies revealed that mepolizumab treat-
ment not only reduced eosinophil numbers in the blood and 
sputum but also significantly reduced asthma exacerbations 
together with the demonstration that mepolizumab attenu-
ated aspects of eosinophil-induced airway inflammation 
refractive to glucocorticoid therapy.17,18 These are important 
observations as they strongly support the development of 
discriminatory biomarkers and genetic profiling to identify 
patients with particular subphenotypes of asthma to guide 
anticytokine therapy targeting to those most likely to exhibit 
clinically beneficial effects.
Reslizumab: synthesis  
and preclinical development
Reslizumab (Cinquil™; Teva Pharmaceutical Industries Ltd, 
Petach Tikva, Israel [formerly SCH-55700]) was humanized 
from an anti-IL-5 antibody (JES1-39D10), originally raised 
in rats, and exhibited an extremely long duration of action 
in mice, monkeys, and guinea pigs.19,20 Reslizumab was 
synthesized by complementarity-determining region graft-
ing of 39D10 to produce a humanized IgG4/κ antibody with 
high affinity for human IL-5, with a dissociation constant of 
81 pM, and an association rate constant of 4.9 × 105 per M/s. 
Proliferation of human erythroleukemia cells induced by IL-5 
was inhibited by reslizumab with an EC50 value of 45 pM. 
Reslizumab was evaluated in a number of animal models that 
feature eosinophilic inflammation.21 For example, pulmonary 
eosinophilia in allergic mice and Ascaris-responsive mon-
keys was inhibited by a single dose of reslizumab (1 mg/kg 
intraperitoneally, and 0.3 mg/kg intravenously, respectively). 
The effect of reslizumab was sustained for 6 months after 
administration in monkeys, with 75% inhibition of eosinophil 
accumulation in response to Ascaris challenge observed.22 In 
an ovalbumin-sensitized guinea pig model, intravenous resli-
zumab (0.03 mg/kg, 1 mg/kg, and 30 mg/kg) administered 
2 hours before the ovalbumin challenge reduced eosinophilia, 
airway hyperreactivity, and bronchoconstriction. In a similar 
model that used ovalbumin-sensitized rabbits, intravenous 
reslizumab (5 mg/kg intravenously) administered 2 hours 
before the ovalbumin challenge reduced eosinophil influx 
into the skin, but did not affect the total number of cells and 
neutrophils in the skin.20
Clinical development
Asthma
In an early clinical trial in patients with severe asthma 
whose symptoms were not controlled by inhaled cortico-
steroids, treatment with reslizumab did not result in signifi-
cant improvements in asthma symptoms or lung function, 
although there was a profound reduction in circulating 
eosinophils. Reslizumab exhibited a terminal half-life of 
approximately 25 days in asthmatic patients with doses of 
0.3 mg/kg or greater, giving rapid decreases in peripheral 
blood eosinophilia. Maximal effect on the latter was observed 
at a dose of 1.0 mg/kg that was sustained for at least 4 weeks 
after administration with a return to baseline values within 5 
to 6 months after the dose.12 A recent Phase II, randomized, 
placebo-controlled, multicenter trial evaluated intravenous 
reslizumab in patients with poorly controlled asthma who 
exhibited a sputum eosinophilia greater than 3% and whose 
symptoms were not controlled by a high-dose inhaled gluco-
corticoid. Compared with placebo (n = 53), the reslizumab 
group (n = 53; 3.0 mg/kg) exhibited a significant decrease in 
sputum eosinophilia together with a modest (reslizumab, −0.7; 
placebo, −0.3) but nonsignificant (P = 0.054) improvement 
in asthma control as assessed by the Asthma Control Ques-
tionnaire score, the primary study endpoint. In patients with 
concomitant nasal polyposis, a hallmark of eosinophilic 
disease in patients with asthma,23 reslizumab treatment was 
associated with a significant improvement in asthma symp-
toms (reslizumab, −1.0; placebo, −0.1; P = 0.012). There 
was a nonsignificant reduction in asthma exacerbations in 
the reslizumab group while the adverse event profile for 
reslizumab and placebo were similar without evidence of 
rebound eosinophilia.24 These findings have led to the instiga-
tion of several asthma Phase III clinical trials of reslizumab, 
and these are currently underway.25
Eosinophilic esophagitis
Eosinophilic esophagitis (EE) is a relatively newly  recognized 
severe inflammatory condition of the esophagus that is often 
linked with gastroesophageal reflux disease and a marked 
association with allergic disease. There is a strong (70%) 
gender predisposition for males. Symptoms are  difficult to 
treat and include problems with swallowing, food  impaction, 
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 vomiting, chest pain, tissue remodeling, and stricture 
 formation.26 Eosinophils are absent from the healthy esopha-
gus, and EE is characterized by a marked mucosal eosinophil 
accumulation with a count of more than 15 cells per high 
power field, which is considered diagnostic for this  condition. 
EE is widely seen as an idiopathic condition, reflecting the 
rather poor understanding of the underlying pathogenic 
 mechanisms.27 It is thought that a marked Th2-driven com-
ponent in response to both food and environmental allergens 
drives the accumulation of eosinophils in the esophageal 
mucosa. However, it is clear that this is a complex disease 
with major contributions also made by genetic predisposi-
tion, environmental exposure, allergen sensitization, together 
with the involvement of other cells and mediators in addi-
tion to  eosinophils.28 Clinical studies have demonstrated 
increased levels of IL-5 messenger ribonucleic acid in tissue 
samples from patients with EE compared to control subjects. 
Furthermore, intracellular IL-5 levels were elevated in 
peripheral blood CD4-positive T cells of EE patients com-
pared to control subjects.29 Anti-IL-5 therapy may therefore 
have inhibitory effects on eosinophil trafficking and survival 
with a positive local effect in the esophagus.
A recent double-blind placebo-controlled trial exam-
ined the effect of reslizumab treatment in 226 children or 
adolescents with long standing EE symptoms and signifi-
cant esophageal eosinophilia.30 Patients received 1 mg/kg, 
2 mg/kg, or 3 mg/kg of intravenous reslizumab or placebo 
approximately every 28 days for a total of four doses. The pri-
mary endpoint was improvement of clinical signs and symp-
toms and a reduction of eosinophil count. Patients treated 
with reslizumab had statistically significant and clinically 
relevant reductions in esophageal intraepithelial eosinophil 
counts compared with the placebo group. However, these 
reductions were not accompanied by significant differences 
between the reslizumab and placebo groups in assessments 
of clinical symptoms and quality of life.30 These findings are 
suggestive that other proinflammatory cells, such as mast 
cells, may drive disease activity such that eosinophil dele-
tion does not result in the expected reduction in symptoms. 
The authors also pointed out that monitoring of subjects in 
the clinical trial setting would have led to greater adherence 
to exclusion diets of known food triggers leading to clinical 
improvement in the placebo group.30
It should also be remembered that other mediators are 
potent attractants for eosinophils. For example, eotaxin-3 is 
a potent chemotactic chemokine for eosinophils, and a gene 
polymorphism for eotaxin-3 has been shown to be  associated 
with EE.31 Moreover, IL-5 responses of tissue  eosinophils 
may be inhibited as bronchoalveolar lavage-derived 
 eosinophils from asthmatic subjects,32,33 or those present 
in nasal polyp (NP) tissue,34 exhibit downregulation of the 
membrane-anchored IL-5Rα isoform, while the antagonistic 
soluble IL-5Rα variant is upregulated compared with levels 
seen in peripheral blood.
Nasal polyposis
Bilateral NPs are often present in patients with chronic 
rhinosinusitis, the latter condition is frequently associated 
with asthma. NPs are characterized by an abundance of 
eosinophils in more than 80% of cases. This has raised the 
possibility of a role for anti-IL-5 treatment for this  condition. 
A double-blind, placebo-controlled, randomized, two-center 
safety and pharmacokinetic study investigated the effect 
of a single intravenous dose of reslizumab (3 mg/kg or 
1 mg/kg) on 24 subjects with bilateral NPs. Reslizumab 
treatment reduced eosinophil numbers in peripheral blood 
together with eosinophil cationic protein concentrations in 
nasal secretions for up to 8 weeks after treatment. However, 
significant reductions in individual NP size only occurred in 
half of the treated patients with responder patients exhibit-
ing increased IL-5 concentrations (.40 pg/mL) in nasal 
secretions at baseline compared with nonresponders.35 The 
authors concluded that the selection of appropriate NP 
patients on the basis of IL-5 in their nasal secretions is an 
important consideration when planning clinical trials with 
IL-5 antagonists.
Hypereosinophilic syndrome
Hypereosinophilic syndrome (HES) is a heterogeneous 
group of disorders characterized by the presence of unex-
plained eosinophilia (.1.5 × 109/L . 1500/mm3) resulting 
in end organ damage. Four patients with HES refractory to 
or intolerant of therapy with corticosteroids, hydroxyurea, 
and interferon-α were treated with a single injection of 
reslizumab (1 mg/kg intravenously). Two patients responded 
to treatment with reslizumab, exhibiting a rapid decrease in 
eosinophilia accompanied by marked improvement in their 
symptoms. These positive responses were prolonged, lasting 
for more than 30 days following the mAb infusion. However, 
there was a rebound in the peripheral eosinophil count in both 
subjects at 6 to 8 weeks after treatment compared to baseline, 
and a severe exacerbation of symptoms preceded by a rise 
in serum IL-5 detectable at 1 month after treatment.36 HES 
represents a very rare group of conditions making it difficult 
to recruit sufficient patient numbers to a given clinical trial 
even in the multicenter setting.
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Conclusion
The development of novel antiinflammatory asthma therapy 
based on targeting cytokines has proven to be for the most 
part disappointing, with the majority of biologics proving 
inadequate in the clinical setting in asthma, even though they 
were highly effective in animal models of asthma. The latter 
is most likely due to the artificially-induced airway inflam-
mation in animal models, which is not a true representation 
of the wide spectrum of pathologies observed in asthmatic 
patients. To date, reslizumab has yet to be convincingly 
proven as an effective treatment for eosinophilic asthma, but 
the development of discriminatory biomarkers and genetic 
profiling may identify patients with particular subphenotypes 
of asthma, allowing therapy to be targeted to those most likely 
to exhibit beneficial effects.
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